

Contents

- ix Editors' Message
- x Reviewers
- xi Continuing Medical Education Information

Ham-Wasserman Lecture

- 1 Leukemogenesis in infants and young children with trisomy 21**
IRENE ROBERTS

Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets

- 9 Achieving MRD negativity in AML: how important is this and how do we get there?**
CHRISTOPHER S. HOURIGAN
- 15 Novel investigational approaches for high-risk genetic subsets of AML: *TP53*, *KMT2A*, *FLT3***
KIERAN D. SAHASRABUDHE AND ALICE S. MIMS
- 23 Optimizing outcomes in secondary AML**
ANDREW MATTHEWS AND KEITH W. PRATZ
- 30 EVIDENCE-BASED MINIREVIEW**
Clinical utilization of panel-based molecular testing for patients with AML
BRANDON J. AUBREY AND ANDREW BRUNNER

Anxiety Provoking Consultations: Mast Cells and Eosinophils

- 34 Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms**
JASON GOTLIB
- 47 Approach to the patient with suspected hypereosinophilic syndrome**
AMY D. KLION
- 55 How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms**
CEM AKIN

Are Alternative Donors Now Mainstream in Allogeneic Transplant?

- 64 In 2022, which is preferred: haploidentical or cord transplant?**
ARNON NAGLER AND MOHAMAD MOHTY
- 74 New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)**
SHUKAIB ARSLAN AND MONZR M. AL MALKI
- 83 Hematology 2022—what is complete HLA match in 2022?**
STEPHEN R. SPELLMAN

Autoimmune Hemolytic Anemias

- 90 Cold AIHA and the best treatment strategies**
JENNY MCDADE DESPOTOVIC AND TAYLOR OLMSTED KIM
- 96 Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies**
SUSAN T. JOHNSON AND KATHLEEN E. PUCA
- 105 Warm autoimmune hemolytic anemia and the best treatment strategies**
DAVID J. KUTER

Beyond Routine Frontline Therapy of CML

- 114 Transplantation in CML in the TKI era: who, when, and how?**
CHRISTIAN NIEDERWIESER AND NICOLAUS KRÖGER
- 123 Treatment of CML in pregnancy**
HARRY F. ROBERTSON AND JANE F. APPERLEY
- 129 Management of TKI-resistant chronic phase CML**
TIMOTHY P. HUGHES AND NARANIE SHANMUGANATHAN

Controversies in Aggressive NHL

- 138 CNS prophylaxis in aggressive B-cell lymphoma**
MATTHEW R. WILSON, SABELA BOBILLO, AND KATE CWYNARSKI
- 146 Sequencing therapy in relapsed DLBCL**
CHRISTOPHER R. FLOWERS AND OREOFE O. ODEJIDE
- 155 What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?**
ANITA KUMAR

Immunotherapy in Multiple Myeloma

- 163 Antibodies and bispecifics for multiple myeloma: effective effector therapy**
CHRISTOPHER CIPKAR, CHRISTINE CHEN, AND SUZANNE TRUDEL
- 173 Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma**
SARAH A. HOLSTEIN
- 180 Cellular therapy for multiple myeloma: what's now and what's next**
PAULA RODRIGUEZ-OTERO AND JESÚS F. SAN-MIGUEL

Improving Outcomes in ALL

- 190 New developments in ALL in AYA**
NICOLAS BOISSEL
- 197 Optimal approach to T-cell ALL**
KRISTEN M. O'DWYER
- 206 Ph+ ALL in 2022: is there an optimal approach?**
MATTHEW J. WIEDUWILT
- 213 EVIDENCE-BASED MINIREVIEW**
What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
FADI G. HADDAD AND NICHOLAS J. SHORT

JAK/STAT Inhibition and Beyond in Ph-Negative MPNs

- 218 Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts**
JAN PHILIPP BEWERSDORF AND RAAJIT K. RAMPAL

225 Molecular prognostication in Ph-negative MPNs in 2022

ALESSANDRO MARIA VANNUCCHI AND PAOLA GUGLIELMELLI

235 New approaches to tackle cytopenic myelofibrosis

SAMUEL B. REYNOLDS AND KRISTEN PETTIT

Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies

245 Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies

SMITA BHATIA

251 Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity

WENDY BOTTINOR AND ERIC J. CHOW

259 Risk factors and screening for neurocognitive impacts of therapy

KEVIN R. KRULL

Long-Term Health Effects of Curative Therapy for Sickle Cell Disease

266 Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease

COURTNEY D. FITZHUGH

272 Long-term health outcomes following curative therapies for sickle cell disease

ROHINI CHAKRAVARTHY AND DEBRA L. FRIEDMAN

277 Organ function indications and potential improvements following curative therapy for sickle cell disease

MONICA L. HULBERT, ALLISON A. KING, AND SHALINI SHENOY

283 EVIDENCE-BASED MINIREVIEW

How to utilize new therapies for sickle cell disease

STEPHANIE GUARINO AND SOPHIE LANZKRON

Managing Thrombocytopenia in Challenging Situations

286 Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem

HANNY AL-SAMKARI

296 Thrombocytopenia and liver disease: pathophysiology and periprocedural management

HANA I. LIM AND ADAM CUKER

303 Thrombocytopenia in pregnancy

ALLYSON M. PISHKO AND ARIELA L. MARSHALL

312 EVIDENCE-BASED MINIREVIEW

Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia

RUSHAD PATELL AND JEFFREY I. ZWICKER

Maximizing Outcomes in CLL

316 Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax

LYDIA SCARFÒ

323 Selecting initial therapy in CLL

INHYE E. AHN AND JENNIFER R. BROWN

329 Treatment of Richter's syndrome

PHILIP A. THOMPSON AND TANYA SIDDIQI

Multiple Myeloma: Assessing the Patient and the Disease

337 Fitness and frailty in myeloma

CHARLOTTE PAWLYN, ABDULLAH M. KHAN, AND CIARA L. FREEMAN

- 349 High or low? Assessing disease risk in multiple myeloma**
TIMOTHY MARTIN SCHMIDT
- 356 The burden of myeloma: novel approaches to disease assessment**
MATTHEW HO AND TAXIARCHIS KOURELIS
- 363 Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy**
FAHRETTIN COVUT AND KRISTEN M. SANFILIPPO

Novel Approaches in MDS

- 368 New investigational combinations for higher-risk MDS**
KRISTIN L. KOENIG AND UMA BORATE
- 375 Risk stratifying MDS in the time of precision medicine**
MARIO CAZZOLA
- 382 Targeting inflammation in lower-risk MDS***
JESUS D. GONZALEZ-LUGO AND AMIT VERMA

Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries

- 388 Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy**
EUGENIA VICKY ASARE, MICHAEL R. DEBAUN, EDEGHONGHON OLAYEMI, THEODORE BOAFOR, AND SAMUEL A. OPPONG
- 408 Evidence-based management of pregnant women with sickle cell disease in high-income countries**
EUGENE OTENG-NTIM AND PANICOS SHANGARIS
- 414 Evidence-based obstetric management of women with sickle cell disease in low-income countries**
BOSEDE B. AFOLABI, OCHUWA A. BABAH, AND TITILOPE A. ADEYEMO

Prophylactic Platelet Transfusions

- 421 Novel platelet products including cold-stored platelets**
DANA V. DEVINE
- 424 Expanding the platelet inventory to mitigate the impact of severe shortages**
JAMES R. STUBBS, BETH H. SHAZ, RALPH R. VASSALLO, AND JOHN D. ROBACK
- 430 Platelet components and bacterial contamination: hospital perspective 2022**
ZBIGNIEW M. SZCZEPIORKOWSKI AND MONICA B. PAGANO
- 437 EVIDENCE-BASED MINIREVIEW**
Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia
DEBBIE JIANG AND SANDHYA R. PANCH

Reproductive and Sexual Health in Sickle Cell Disease

- 442 Incorporating gonadal health counseling into pediatric care of sickle cell patients**
LILLIAN R. MEACHAM, LYDIA H. PECKER, BEATRICE GEE, AND ADRIENNE MISHKIN
- 450 Epidemiology and treatment of priapism in sickle cell disease**
IBRAHIM M. IDRIS, ARTHUR L. BURNETT, AND MICHAEL R. DEBAUN
- 459 No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease**
LYDIA H. PECKER, ALECIA NERO, AND MINDY CHRISTIANSON

Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

- 467 Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation**
EMMA DELOUGHERY AND BETHANY SAMUELSON BANNOW
- 474 Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia**
KOCHAWAN BOONYAWAT AND PANTEP ANGCHAIUKSIRI

481 Thrombosis questions from the inpatient wards

GEORGE GOSHUA, PAVAN K. BENDAPUDI, AND ALFRED IAN LEE

491 EVIDENCE-BASED MINIREVIEW

Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?

GEORGE GOSHUA AND PAVAN K. BENDAPUDI

Thrombosis Prevention and Treatment

495 Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism

OMRI COHEN AND WALTER AGENO

506 To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients

ALEX C. SPYROPOULOS

515 The 5 most frequently asked questions about factor Xa inhibitors

TZU-FEI WANG AND MARC CARRIER

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease

522 Transplant for TP53-mutated MDS and AML: because we can or because we should?

JURJEN VERSLUIS AND R. COLEMAN LINDSLEY

528 Transplant in AML with measurable residual disease: proceed or defer?

CHARLES CRADDOCK

534 Allogeneic transplantation for advanced acute leukemia

DANIEL WEISDORF

Treatment Approaches for the Multiple Myeloma Patient in 2022

539 Newly diagnosed multiple myeloma: making sense of the menu

CAITLIN L. COSTELLO

551 The consultant's guide to smoldering multiple myeloma

SIGRUN THORSTEINSDOTTIR AND SIGURDUR YNGVI KRISTINSSON

560 The first relapse in multiple myeloma: how to pick the next best thing

SRINIVAS DEVARAKONDA, NIDHI SHARMA, AND YVONNE EFEBERA

Update in Hemophilia

569 Gene therapy for hemophilia

AMIT C. NATHWANI

579 Long-term prophylaxis: what are our options and how to define success?

MARILYN JEAN MANCO-JOHNSON AND BETH BOULDEN WARREN

586 Perioperative hemostasis for patients with hemophilia

JACQUELINE N POSTON AND REBECCA KRUSE-JARRES

Updates in Targeted Therapy in Pediatric Leukemia

594 Clinical screening for Ph-like ALL and the developing role of TKIs

THAI HOA TRAN AND SARAH K. TASIAN

603 The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies

LAUREN POMMERT AND KATHERINE TARLOCK

611 Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy

RISHI S. KOTECHA

Von Willebrand Disease

- 618 Diagnostic pitfalls and conundrums in type 1 von Willebrand disease**
ROBERT F. SIDONIO AND MICHELLE LAVIN
- 624 Special considerations in GI bleeding in VWD patients**
NICHOLAS L.J. CHORNENKI, EDWIN OCRAN, AND PAULA D. JAMES
- 631 What have we learned about the patient's experience of von Willebrand disease?
A focus on women**
HEATHER VANDERMEULEN, SUMEDHA ARYA, SARAH NERSESIAN, NATALIE PHILBERT, AND MICHELLE SHOLZBERG

What is New in Classical Bone Marrow Failure Syndromes? (Focus on Management)

- 637 Dyskeratosis congenita and telomere biology disorders**
SHARON A. SAVAGE
- 649 Modern management of Fanconi anemia**
CARLO DUFOUR AND FILOMENA PIERRI
- 658 Genetics of severe congenital neutropenia as a gateway to personalized therapy**
JEAN DONADIEU AND CHRISTINE BELLANNÉ-CHANTELOT

What's New in Indolent Lymphoma

- 666 Divergent paths: management of early relapsed follicular lymphoma**
RADHIKA TAKIAR, YASMIN KARIMI, AND TYCEL J. PHILLIPS
- 676 Management of marginal zone lymphomas**
MICHELE MERLI AND LUCA ARCAINI
- 688 Biology of follicular lymphoma: insights and windows of clinical opportunity**
MEGAN PERRETT, CARINA EDMONDSON, AND JESSICA OKOSUN
- 695 EVIDENCE-BASED MINIREVIEW**
When should autologous transplant or cellular therapy be considered for follicular lymphoma?
DAVID A. BOND AND AJAY K. GOPAL

Where Are We Headed in Hodgkin Lymphoma?

- 699 Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?**
ALISON J. MOSKOWITZ
- 706 Incorporating novel agents into frontline treatment of Hodgkin lymphoma**
SWETHA KAMBHAMPATI AND ALEX F. HERRERA
- 717 Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma**
SVEN BORCHMANN

Errata

- 723 Perioperative consultative hematology: can you clear my patient for a procedure? *Hematology Am Soc Hematol Educ Program.* 2021;2021:521–528.**
BURNETT AE, RAGHEB B, KAATZ S.
- 724 Noninfectious complications of hematopoietic cell transplantation. *Hematology Am Soc Hematol Educ Program.* 2021;2021:578–586.**
WILLIAMS KM.
- 725 COVID-19 and thrombosis: searching for evidence. *Hematology Am Soc Hematol Educ Program.* 2021;2021:621–627.**
THILAGAR B, BEIDOUN M, RHOADES R, KAATZ S.

*Note

The article "Targeting inflammation in lower-risk MDS" beginning on page 382 is not eligible for continuing medical education (CME) credit.